Target intelligence / Profile preview

Immune microenvironment

Molecular classification
Other
01

Overview

The immune microenvironment refers to the dynamic, context-dependent community of immune cells (such as T cells, B cells, macrophages, dendritic cells, myeloid-derived suppressor cells), soluble mediators (cytokines, chemokines), and stromal elements surrounding tissues (commonly, tumors). Its composition and function can promote effective immune surveillance against abnormal cells (tumor or infected), but may also become dysregulated, contributing to immune escape, chronic inflammation, or tissue damage. In cancer, the tumor immune microenvironment profoundly influences tumor progression, immune evasion, therapy response, and the effectiveness of immunotherapies.

Other names
Tumor immune microenvironment (in cancer research)TIME (in the context of tumors)Immune landscapeTumor microenvironment – immune compartment
02

Mechanism of action

Modulation of immune checkpoints (restoring T cell activity, e.g., PD-1/PD-L1 blockade); Depletion or reprogramming of suppressive immune cells (e.g., targeting Tregs, MDSCs); Recruitment/activation of effector immune cells (e.g., CAR-T cells); Inhibiting pro-tumor cytokine/chemokine signaling; Enhancing antigen presentation and immune priming. These mechanisms act via cellular interactions and signal-modulation within the immune microenvironment.

03

Biological functions

Immune responseImmune surveillanceImmune evasionTumor cell recognitionRegulation of inflammationTissue homeostasisImmune suppression
04

Disease associations

CancerInflammationInfectionAutoimmunityOther
05

Safety considerations

Immune-related adverse events (irAEs) with checkpoint blockadeCytokine release syndrome (e.g., CAR-T therapy)AutoimmunityOff-tumor, on-target effects
06

Interacting drugs

Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)

3 more in the full profile.

07

Biomarkers

PD-L1 expressionTumor-infiltrating lymphocyte (TIL) densityImmune gene signatures (“hot” vs. “cold” tumors)Expression of immune checkpoints (PD-1, CTLA-4, LAG3, TIM3)Myeloid-derived suppressor cell (MDSC) markersInterferon-γ response markers

Beyond the preview

Go deeper on Immune microenvironment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune microenvironment.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call